KRAS and pancreatic neoplasm: These data thus hint at a potential therapeutic synergism of combined KRAS and MEK inhibition by AMG510 plus Binimetinib in combination with 2 Gy irradiation in KRAS G12C mutated MiaPaCa pancreatic cancer cells (Figure 2a,b).